Physician profile
Ivan Hadad
NPI 1043477516
$4,387.64
in general payments reported to CMS, 2019-2025
11 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $194 · 2021: $140 · 2022: $253 · 2023: $418 · 2024: $2,811 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,329 · Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,328.75 |
| Food and Beverage | $1,125.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $2,598.97 | 2024-2025 | Durasorb Monofilament Mesh, Integra, Integra Dermal Regeneration Template |
| Abbvie INC. | $665.30 | 2023-2025 | |
| Kls-Martin L.P. | $356.76 | 2019-2021 | |
| Axogen | $236.49 | 2019-2023 | Avance Nerve Graft |
| Allergan, INC. | $149.90 | 2022 | |
| Vioptix INC | $119.28 | 2019 | |
| Smith+Nephew, INC. | $103.23 | 2022 | |
| Baxter Healthcare | $85.32 | 2020 | |
| Kerecis Limited | $33.68 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Tela Bio, INC. | $21.98 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Mentor Worldwide LLC | $16.73 | 2024 | Mentor Memorygel Resterilizable Gel Sizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Hadad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.